Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Maravai Lifesciences Holdings Inc Cl A (MRVI)

Maravai Lifesciences Holdings Inc Cl A (MRVI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,215,782
  • Shares Outstanding, K 252,237
  • Annual Sales, $ 288,950 K
  • Annual Income, $ -119,030 K
  • EBIT $ -44 M
  • EBITDA $ 8 M
  • 60-Month Beta 0.02
  • Price/Sales 4.04
  • Price/Cash Flow 48.89
  • Price/Book 1.90

Options Overview Details

View History
  • Implied Volatility 81.63% ( +11.08%)
  • Historical Volatility 148.40%
  • IV Percentile 31%
  • IV Rank 41.83%
  • IV High 164.54% on 10/24/24
  • IV Low 22.00% on 05/31/24
  • Put/Call Vol Ratio 0.29
  • Today's Volume 80
  • Volume Avg (30-Day) 116
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 4,518
  • Open Int (30-Day) 4,503

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.06
  • Number of Estimates 5
  • High Estimate -0.05
  • Low Estimate -0.08
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.28 +16.02%
on 11/18/24
8.53 -41.89%
on 10/22/24
-3.54 (-41.65%)
since 10/21/24
3-Month
4.28 +16.02%
on 11/18/24
9.60 -48.33%
on 09/06/24
-3.82 (-43.51%)
since 08/21/24
52-Week
4.28 +16.02%
on 11/18/24
11.56 -57.07%
on 05/17/24
+0.03 (+0.61%)
since 11/21/23

Most Recent Stories

More News
Maravai LifeSciences Announces November 2024 Investor Conference Schedule

MRVI : 4.97 (+3.11%)
Maravai LifeSciences (MRVI) Q3 2024 Earnings Call Transcript

MRVI earnings call for the period ending September 30, 2024.

MRVI : 4.97 (+3.11%)
Maravai LifeSciences Reports Third Quarter 2024 Financial Results

MRVI : 4.97 (+3.11%)
Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 7, 2024

MRVI : 4.97 (+3.11%)
Maravai LifeSciences (MRVI) Q2 2024 Earnings Call Transcript

MRVI earnings call for the period ending June 30, 2024.

MRVI : 4.97 (+3.11%)
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics

- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability -- Applied DNA Secures Commercial Linea RNAP Quantity Sufficient...

APDN : 0.1560 (-5.45%)
MRVI : 4.97 (+3.11%)
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics

- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability -- Applied DNA Secures Commercial Linea RNAP Quantity Sufficient...

APDN : 0.1560 (-5.45%)
MRVI : 4.97 (+3.11%)
Maravai LifeSciences (MRVI) Q1 2024 Earnings Call Transcript

MRVI earnings call for the period ending March 31, 2024.

MRVI : 4.97 (+3.11%)
Maravai LifeSciences (MRVI) Q4 2023 Earnings Call Transcript

MRVI earnings call for the period ending December 31, 2023.

MRVI : 4.97 (+3.11%)
Maravai LifeSciences (MRVI) Q3 2023 Earnings Call Transcript

MRVI earnings call for the period ending September 30, 2023.

MRVI : 4.97 (+3.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Maravai LifeSciences Holdings Inc. is a life sciences company providing products for the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company offer products and services in the fields of nucleic acid synthesis, bioprocess impurity detection and...

See More

Key Turning Points

3rd Resistance Point 5.48
2nd Resistance Point 5.27
1st Resistance Point 5.04
Last Price 4.97
1st Support Level 4.61
2nd Support Level 4.40
3rd Support Level 4.17

See More

52-Week High 11.56
Fibonacci 61.8% 8.77
Fibonacci 50% 7.91
Fibonacci 38.2% 7.06
Last Price 4.97
52-Week Low 4.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar